Takeda invests in Fate Therapeutics

Tuesday, May 10, 2011 12:22 PM

Japan-based Takeda has made a strategic investment in the U.S.-based Fate Therapeutics, a privately-held firm that specializes in stem cell research, according to Pharma Times.

The investment has been made via the Japanese drugmaker's corporate venture arm, Takeda Ventures, and is designed to expand Takeda’s portfolio in regenerative medicine.

Fate’s first therapeutic candidate is now in phase Ib studies in hematopoietic reconstitution in patients with malignancies such as leukemia and lymphoma.

Takeda says its new partner utilizes "the most advanced biologics and reprogramming technologies for identifying promising points of therapeutic intervention." Fate has secured backing from venture firms and the investment arms of Astellas and Genzyme.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs